Core 3: Patient Data

项目摘要 总体而言，这一核心的主要工作将是为接受RPT的患者进行一项主要的成像试验 在约翰·霍普金斯大学的治疗，以及在调查人员之间建立深入的研究合作， 合作者和行业赞助商。对于目标1，核心调查员将进行一次主要的成像试验 (参阅ToTreat)，以获取P01项目的数据，灵活地包括接受标准护理或 研究其他协议上的RPT。对于目标2，斯古罗斯博士、基斯博士和研究人员已经建立了 与拜耳(227-HER2-TTC和227-PSMA-TTC)、Rayzebio(225Ac-TTC)的深度研究合作 DOTATATE)和康奈尔大学(225Ac-J591)，以支持P01项目以及未来的协作工作。这些 研究合作将包括共享已完成和正在进行的临床研究的图像和数据， 包括SPECT剂量学、PET替代图像和响应数据。行业研究协议包括 现在完全执行了。对于AIMS 3和AIMS 4，核心将建立一个去识别的RPT图像数据库，吸收 剂量、肿瘤反应和毒性数据。这将包括从SEEtoTREAT、Ravens和 来自工业界和学术界的合作者。

Project Summary Overall, the primary effort of this Core will be to conduct a master imaging trial for patients undergoing RPT treatment at Johns Hopkins, as well as to establish deep research collaborations among investigators, collaborators and industry sponsors. For Aim 1, the Core Investigators will conduct a master imaging trial (SeeToTreat) to acquire data for the P01 projects, with flexibility to include patients receiving standard of care or research RPT on other protocols. For Aim 2, Dr. Sgouros, Dr. Kiess and the research staff have established deep research collaborations with Bayer (227Th-HER2-TTC and 227Th-PSMA-TTC), Rayzebio (225Ac- DOTATATE), and Cornell (225Ac-J591) to support the P01 Projects as well as future collaborative work. These research collaborations will include sharing of images and data from completed and ongoing clinical studies, including SPECT dosimetry, PET surrogate images and response data. The industry research agreements are now fully executed. For Aims 3 and 4, the Core will establish a de-identified RPT database of images, absorbed dose, tumor response and toxicity data. This will include collection of data from SEEtoTREAT, RAVENS, and from industry and academic collaborators.